Annexon, Inc.
tanruprubart
Guillain-Barré Syndrome (GBS)
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on tanruprubart for Guillain-Barré Syndrome (GBS) is expected Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“Tanruprubart: Potential to be the first targeted and fast-acting therapy for GBS, a leading cause of neuromuscular paralysis impacting 150,000 people annually worldwide.”